{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:55:37Z","timestamp":1781758537986,"version":"3.54.5"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of T-DM1 versus trastuzumab plus pertuzumab in adjuvant treatment of HER2-positive breast cancer patients with residual invasive disease after neoadjuvant therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study retrospectively analyzed 184 patients treated at Renmin Hospital of Wuhan University from January 2019 to January 2022. The patients were divided into a T-DM1 treatment group and a dual-target treatment group based on whether they received T-DM1 or trastuzumab plus pertuzumab during adjuvant therapy. Clinical and pathological data of the two groups were collected before and after surgery, and follow-up was conducted. The primary study endpoint was disease-free survival (DFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Disease progression occurred in 20.3% of the dual-target treatment group and 12.6% of the T-DM1 treatment group. Although T-DM1 was associated with a 38% reduction in recurrence risk, the difference was not statistically significant (HR: 0.62, 95% CI: 0.30-1.26, P\u00a0=\u00a00.19). Exploratory subgroup analyses suggested improved DFS with T-DM1 in patients with initially unresectable disease, preoperative lymph node positivity, or poor pathological response (MP 1\u20133 or RCB III); In terms of safety, both groups of patients were consistent with the known safety profile. No treatment-related deaths occurred. Grade \u22653 thrombocytopenia was significantly more frequent with T-DM1 (8.45% vs 0.88%, P\u00a0=\u00a00.01), representing a clinically important toxicity trade-off.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The use of T-DM1 in the adjuvant setting suggests improved disease-free survival in HER2-positive non-pCR patients who were initially inoperable, had preoperative lymph node positivity, or exhibited poor pathological response (MP grade 1\u20133 or RCB III).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1806399","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:38:08Z","timestamp":1781757488000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Academic Affairs, School of Medicine, Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichong","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1200\/JCO.22.02241","article-title":"Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer","volume":"41","author":"van Mackelenbergh","year":"2023","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61964-4","article-title":"Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2021.1609785","article-title":"Pathologic complete response rates after neoadjuvant pertuzumab and trastuzumab with chemotherapy in early stage HER2-positive breast cancer - increasing rates of breast conserving surgery: a real-world experience","volume":"27","author":"Boer","year":"2021","journal-title":"Pathol Oncol Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1038\/s41467-024-45591-7","article-title":"Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial","volume":"15","author":"Huang","year":"2024","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21037\/gs.2020.03.11","article-title":"The Peony trial: adding evidence to pertuzumab use in non-metastatic breast cancer","volume":"9","author":"Cortadellas","year":"2020","journal-title":"Gland Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02505","article-title":"Adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2-positive breast cancer in the APHINITY trial: third interim overall survival analysis with efficacy update","author":"Loibl","year":"2024","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.01.031","article-title":"Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial","volume":"166","author":"Gelber","year":"2022","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN guidelines(R) insights: breast cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.19401\/j.cnki.1007-3639.2023.12.004","article-title":"Chinese anti-cancer association guidelines and standards for breast cancer diagnosis and treatment (2024 edition)","volume":"33","author":"Shao","year":"2023","journal-title":"China Cancer J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.4999","article-title":"Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis","volume":"32","author":"Dieras","year":"2014","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2019.10.001","article-title":"Predicting thrombocytopenia in patients with breast cancer treated with ado-trastuzumab emtansine","volume":"20","author":"Modi","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s12282-023-01473-2","article-title":"HER2-targeted antibody-drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia","volume":"30","author":"Rainone","year":"2023","journal-title":"Breast Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3892\/ol.2023.14110","article-title":"Early thrombocytopenia predicts longer time-to-treatment discontinuation in trastuzumab emtansine treatment","volume":"26","author":"Sahin","year":"2023","journal-title":"Oncol Lett"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1806399\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:38:16Z","timestamp":1781757496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1806399\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1806399"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1806399","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1806399"}}